Zolmitriptan

Migraine, Cluster Headache, Liver + 1 more
Treatment
20 Active Studies for Zolmitriptan

What is Zolmitriptan

ZolmitriptanThe Generic name of this drug
Treatment SummaryZolmitriptan is an oral medication used to treat migraine headaches. It belongs to a group of drugs called triptans and is one of the most commonly prescribed medications for this condition. It is available in tablet and nasal spray form under the brand name Zomig. Zolmitriptan can be taken alone or with an NSAID, such as naproxen, to provide the best relief from migraine pain. It was approved by the FDA in 1997 and is considered the gold standard in treating acute migraine attacks.
Zomigis the brand name
image of different drug pills on a surface
Zolmitriptan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zomig
Zolmitriptan
1998
91

Effectiveness

How Zolmitriptan Affects PatientsZolmitriptan is a type of drug called a triptan, which works by activating certain serotonin receptors in the body. It can help reduce the pain of migraines, but can also cause adverse cardiovascular effects such as heart attack, stroke, or arrhythmia. Other side effects of taking Zolmitriptan include chest/throat/neck/jaw pain, tightness, and/or pressure, as well as the possibility of overusing the medication or having a reaction that affects the body's serotonin levels. People with phenylketonuria should be aware that ZOMIG-ZMT contains
How Zolmitriptan works in the bodyMigraines are severe headaches usually accompanied by nausea, light and sound sensitivity, and irritability. The exact cause is not known, but it is thought to involve both the nerves and blood vessels in the brain. Zolmitriptan is a medication used to treat migraines. It works by targeting certain nerve and blood vessels throughout the brain. This helps calm down the nerves and blood vessels, reducing the pain and other symptoms of migraine.

When to interrupt dosage

The recommended dosage of Zolmitriptan is contingent upon the diagnosed affliction, such as Cluster Headache, Migraine and moderate or extreme hepatic insufficiency. The measure varies as per the method of delivery (e.g. Spray, metered - Nasal or Tablet, multilayer, extended release - Oral) recorded in the table beneath.
Condition
Dosage
Administration
Migraine Disorders
, 2.5 mg, 5.0 mg, 1.0 mg, 5.0 mg/pump actuation, 2.5 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Nasal, Spray, metered, Spray, metered - Nasal, Tablet, film coated, Tablet, film coated - Oral, Spray, Nasal; Oral, Spray - Nasal; Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Spray - Nasal
Migraine
, 2.5 mg, 5.0 mg, 1.0 mg, 5.0 mg/pump actuation, 2.5 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Nasal, Spray, metered, Spray, metered - Nasal, Tablet, film coated, Tablet, film coated - Oral, Spray, Nasal; Oral, Spray - Nasal; Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Spray - Nasal
Cluster Headache
, 2.5 mg, 5.0 mg, 1.0 mg, 5.0 mg/pump actuation, 2.5 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Nasal, Spray, metered, Spray, metered - Nasal, Tablet, film coated, Tablet, film coated - Oral, Spray, Nasal; Oral, Spray - Nasal; Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Spray - Nasal
Liver
, 2.5 mg, 5.0 mg, 1.0 mg, 5.0 mg/pump actuation, 2.5 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Nasal, Spray, metered, Spray, metered - Nasal, Tablet, film coated, Tablet, film coated - Oral, Spray, Nasal; Oral, Spray - Nasal; Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Spray - Nasal

Warnings

Zolmitriptan has fourteen contraindications and should not be used in tandem with the conditions provided in the subsequent table.Zolmitriptan Contraindications
Condition
Risk Level
Notes
Coronary Vasospasm
Do Not Combine
cardiac accessory conduction pathway disorders
Do Not Combine
Basilar-Type Migraine
Do Not Combine
Stroke
Do Not Combine
Peripheral Vascular Disease
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Coronary Artery Disease
Do Not Combine
Transient Ischemic Attack
Do Not Combine
Wolff-Parkinson-White Syndrome
Do Not Combine
Hypertensive disease
Do Not Combine
Pulse Frequency
Do Not Combine
intestinal ischemia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Zolmitriptan may interact with Pulse Frequency
There are 20 known major drug interactions with Zolmitriptan.
Common Zolmitriptan Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Methylene blue
Major
Zolmitriptan may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Zolmitriptan may increase the serotonergic activities of Mirtazapine.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Zolmitriptan is combined with Oliceridine.
Zolmitriptan Toxicity & Overdose RiskTaking too much zolmitriptan may lead to serious side effects such as changes to the blood vessels and activation of serotonin receptors. Those who take a single dose of 50 mg may feel drowsy. It is recommended to provide medical support and symptom relief in cases of overdose.
image of a doctor in a lab doing drug, clinical research

Zolmitriptan Novel Uses: Which Conditions Have a Clinical Trial Featuring Zolmitriptan?

65 clinical trials are in progress to investigate the potential of Zolmitriptan in treating moderate to severe hepatic impairment, Cluster Headache and Migraine Disorders.
Condition
Clinical Trials
Trial Phases
Liver
0 Actively Recruiting
Migraine Disorders
0 Actively Recruiting
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Cluster Headache
2 Actively Recruiting
Phase 1, Phase 2

Zolmitriptan Reviews: What are patients saying about Zolmitriptan?

5Patient Review
3/13/2009
Zolmitriptan for Migraine Headache
Extremely effective at treating migraines, but be aware that it can cause drowsiness. I find that I fall asleep and wake up without a migraine, but if I need to stay awake, the medicine makes me feel light-headed and dizzy.
4.7Patient Review
11/20/2019
Zolmitriptan for Migraine Headache
I'm mostly pleased with this product. If I don't take it the second I notice a migraine starting, it's not as effective.
4.3Patient Review
5/13/2008
Zolmitriptan for Migraine Headache
Zolmitriptan has helped me a lot by taking care of my migraines and their neurological symptoms. However, I do get headaches from the medication itself (although they're manageable), as well as some other side effects that can last around 24 hours. These include hot water making my skin tingle, mild dizziness, and generally feeling out-of-it.
4Patient Review
10/9/2010
Zolmitriptan for Migraine Headache
This drug has been effective in treating my headaches; however, the problem is that they tend to come back every day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zolmitriptan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is zolmitriptan a narcotic drug?

"Zomig is a drug that is used to treat migraine pain, but it is not a narcotic."

Answered by AI

How long does zolmitriptan take to work?

"In patients who respond to treatment, Zomig is effective within one hour of taking the medication. Zomig works just as well no matter when it is taken during a migraine attack, but it is best to take it as soon as possible after the migraine begins."

Answered by AI

How does zolmitriptan make you feel?

"Zolmitriptan is a type of medication that is designed to specifically target serotonin receptors. By narrowing the blood vessels around the brain, it is able to effectively stop pain signals from being sent to the brain and also block the release of certain natural substances that can cause a range of symptoms associated with migraines including pain and nausea."

Answered by AI

What is zolmitriptan prescribed for?

"Zolmitriptan is a medication used to treat acute migraine headaches in adults. It is not effective in preventing migraine headaches or treating cluster headaches. Zolmitriptan works by targeting pain receptors in the brain to relieve the pain associated with migraines."

Answered by AI

Clinical Trials for Zolmitriptan

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Have you considered Zolmitriptan clinical trials? We made a collection of clinical trials featuring Zolmitriptan, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Have you considered Zolmitriptan clinical trials? We made a collection of clinical trials featuring Zolmitriptan, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Cocoa Extract for Migraine

18+
All Sexes
Boston, MA
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population. Participants will be asked to: * Provide two urine samples * Complete daily questionnaires * Take four study pills a day for 12 weeks
Recruiting
Dietary Supplement
Brigham and Women's HospitalPamela M Rist, ScD
Have you considered Zolmitriptan clinical trials? We made a collection of clinical trials featuring Zolmitriptan, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security